<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530994</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-EAP</org_study_id>
    <nct_id>NCT04530994</nct_id>
  </id_info>
  <brief_title>A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)</brief_title>
  <official_title>A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      An open-label, single-arm, multi-centre program providing treatment access to ALGS patients&#xD;
      with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd&#xD;
      via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this EAP is to provide access to maralixibat for eligible ALGS patients with&#xD;
      cholestatic pruritus. Participants will be treated with 400 µg/kg/day with safety and&#xD;
      tolerability evaluated on an ongoing basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Alagille Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maralixibat</intervention_name>
    <description>Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent and assent provided, as applicable, per Institutional Review Board&#xD;
             (IRB) or Ethics Committee (EC)&#xD;
&#xD;
          2. Clinical and/or genetic diagnosis of ALGS&#xD;
&#xD;
          3. Male or female participants aged &gt;12 months and ≥5 kg with clinically significant&#xD;
             cholestatic pruritus associated with ALGS&#xD;
&#xD;
          4. Willingness to adhere to an acceptable method of contraception until treatment&#xD;
             discontinuation by females of childbearing potential who are sexually active or who&#xD;
             become sexually active during the program&#xD;
&#xD;
          5. No other therapeutic options or access to any ongoing ALGS clinical trials&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis with a cholestatic liver disease other than ALGS&#xD;
&#xD;
          2. Female who is pregnant or breastfeeding&#xD;
&#xD;
          3. Clinically significant cardiovascular, hepatic, gastro-intestinal, pulmonary,&#xD;
             neurologic, infectious or renal disease or other medical condition that, in the&#xD;
             opinion of the physician or Medical Monitor, would preclude participation in the&#xD;
             program&#xD;
&#xD;
          4. Past medical history of compensated or decompensated cirrhosis&#xD;
&#xD;
          5. Presence of any other disease or condition known to interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of maralixibat or its mode of action&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/alagille-syndrome</url>
    <description>Genetics Home Reference - Alagille syndrome</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>US FDA Resources</description>
  </link>
  <link>
    <url>https://mirumpharma.com</url>
    <description>Mirum Pharmaceuticals homepage</description>
  </link>
  <link>
    <url>https://algseap.com/</url>
    <description>Mirum webpage specific to ALGS EAP</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Disease</keyword>
  <keyword>ALGS</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Cholestasis</keyword>
  <keyword>Pruritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alagille Syndrome</mesh_term>
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

